JP2010525805A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525805A5
JP2010525805A5 JP2010505002A JP2010505002A JP2010525805A5 JP 2010525805 A5 JP2010525805 A5 JP 2010525805A5 JP 2010505002 A JP2010505002 A JP 2010505002A JP 2010505002 A JP2010505002 A JP 2010505002A JP 2010525805 A5 JP2010525805 A5 JP 2010525805A5
Authority
JP
Japan
Prior art keywords
use according
nucleic acid
acid construct
promoter
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010505002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525805A (ja
Filing date
Publication date
Priority claimed from US11/790,992 external-priority patent/US20070286845A1/en
Application filed filed Critical
Publication of JP2010525805A publication Critical patent/JP2010525805A/ja
Publication of JP2010525805A5 publication Critical patent/JP2010525805A5/ja
Pending legal-status Critical Current

Links

JP2010505002A 2007-04-30 2008-04-27 内皮細胞特異性を示すプロモーター及びそのプロモーターを使って血管形成を制御する方法 Pending JP2010525805A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/790,992 US20070286845A1 (en) 2000-11-17 2007-04-30 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
PCT/IL2008/000543 WO2008132729A2 (en) 2007-04-30 2008-04-27 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Publications (2)

Publication Number Publication Date
JP2010525805A JP2010525805A (ja) 2010-07-29
JP2010525805A5 true JP2010525805A5 (enExample) 2011-05-26

Family

ID=38895566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010505002A Pending JP2010525805A (ja) 2007-04-30 2008-04-27 内皮細胞特異性を示すプロモーター及びそのプロモーターを使って血管形成を制御する方法

Country Status (11)

Country Link
US (2) US20070286845A1 (enExample)
EP (1) EP2152317A4 (enExample)
JP (1) JP2010525805A (enExample)
KR (1) KR101525548B1 (enExample)
CN (2) CN103276015A (enExample)
AU (1) AU2008243817B2 (enExample)
CA (1) CA2685394A1 (enExample)
MX (1) MX2009011750A (enExample)
NZ (1) NZ581511A (enExample)
WO (1) WO2008132729A2 (enExample)
ZA (1) ZA200908331B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP2277887A3 (en) * 2001-10-19 2011-02-16 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US20110172293A1 (en) * 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
NZ601325A (en) 2010-01-05 2014-09-26 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
JP6196040B2 (ja) * 2010-01-05 2017-09-13 バスキュラー バイオジェニックス リミテッド 特異的な抗血管形成アデノウイルス剤の使用法
EP2523681A1 (en) * 2010-01-12 2012-11-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
US20130263296A1 (en) * 2010-10-28 2013-10-03 The Johns Hopkins University Cancer imaging with therapy: theranostics
CN104774871A (zh) 2011-02-14 2015-07-15 雷维维科公司 用于血管化异种移植物及其衍生物的异种移植的遗传修饰的猪
HUE042262T2 (hu) 2012-10-17 2019-06-28 Vascular Biogenics Ltd FAS-kimérát kifejezõ adenovírus és alkalmazása rákkezelési módszerekben
EP2951307B1 (en) 2013-02-04 2019-12-25 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
CN107630004B (zh) 2017-09-01 2021-01-15 康希诺生物股份公司 降低可复制性腺病毒产生的细胞株及构建方法和应用
CN111356480A (zh) 2017-10-20 2020-06-30 脉管生物生长有限公司 用于抗血管生成剂疗法的诊断方法
CA3131936A1 (en) 2019-03-13 2020-09-17 Vascular Biogenics Ltd. Methods of anti-tumor therapy
EA202192800A1 (ru) 2019-04-12 2022-03-30 Васкулар Биодженикс Лтд Способы противоопухолевой терапии
CN110714028B (zh) * 2019-11-04 2021-08-31 中国人民解放军第四军医大学 可控性上调Ang-(1-7)靶向性防治低氧性肺动脉高压的表达载体
US20220145258A1 (en) 2020-11-10 2022-05-12 Vessl Therapeutics Ltd Methods of preconditioning vascular cells for transduction, methods of transduction and methods of preserving transduced cells
WO2023044100A1 (en) * 2021-09-20 2023-03-23 Revivicor, Inc. Multitran scenic pigs comprising ten genetic modifications for xenotransplantation
FR3158516A1 (fr) * 2024-01-23 2025-07-25 Asfalia Biologics Production de vecteurs toxiques

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US207985A (en) * 1878-09-10 Improvement in grain-separators
US4866042A (en) * 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6337209B1 (en) * 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
WO1992015680A1 (en) * 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5635385A (en) * 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6579697B1 (en) * 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US8715645B2 (en) * 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US5747340A (en) * 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
US5906827A (en) * 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
CN1136920C (zh) * 1995-02-28 2004-02-04 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
DE69732847T2 (de) * 1996-11-08 2006-04-13 Oklahoma Medical Research Foundation, Oklahoma Endothel-spezifischer expression unter einfluss von epcr kontrollelementen
JP2001513078A (ja) * 1996-12-30 2001-08-28 バテル・メモリアル・インスティテュート 吸入により新生物を治療する製剤とその方法
US6206917B1 (en) * 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
CA2297489A1 (en) * 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
EP0909532A1 (en) * 1997-10-16 1999-04-21 Development Center For Biotechnology Environmentally compatible porous material comprising beneficial nematodes and its preparation
CA2307743A1 (en) * 1997-10-30 1999-05-14 The General Hospital Corporation Bonding of cartilaginous matrices using isolated chondrocytes
US5882893A (en) * 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
WO1999057303A1 (en) * 1998-05-07 1999-11-11 University Of Maryland, Baltimore A method for diagnosing and treating chronic pelvic pain syndrome
US6239151B1 (en) * 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6576265B1 (en) * 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6376244B1 (en) * 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US6265216B1 (en) * 2000-01-20 2001-07-24 Isis Pharmaceuticals, Inc. Antisense modulation of cot oncogene expression
US6866864B2 (en) * 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
US6652583B2 (en) * 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
KR100917854B1 (ko) * 2000-11-17 2009-09-18 바스큘라 바이오제닉스 리미티드 내피세포 특이성을 나타내는 프로모터 및 이를 이용하는방법
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US7067649B2 (en) * 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
EP1207205A1 (en) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenoviral replicons
US6438802B1 (en) * 2001-06-07 2002-08-27 Randolph Scott Beeman Locking mechanism and method for securely fastening resilient cords and tubing
CN1195056C (zh) * 2001-07-12 2005-03-30 钱其军 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法
EP2277887A3 (en) * 2001-10-19 2011-02-16 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US9738907B2 (en) * 2002-02-01 2017-08-22 Oxford Biomedica (Uk) Limited Viral vector
EP1473365A1 (en) * 2002-02-04 2004-11-03 Takeda Chemical Industries, Ltd. Angiogenesis inhibitors
CN1424401A (zh) * 2003-01-06 2003-06-18 李川源 有条件复制型腺病毒及其构建方法和用途

Similar Documents

Publication Publication Date Title
JP2010525805A5 (enExample)
CN108546717A (zh) 反义lncRNA介导顺式调控抑制靶基因表达的方法
JP2012010710A5 (enExample)
Moon et al. Current status of gene therapy for lung cancer and head and neck cancer
JP2009539367A5 (enExample)
US8916378B2 (en) Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy
JP2009219504A5 (enExample)
JP2010259439A5 (enExample)
Cherian et al. An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia
Coupeau et al. Kinetic expression analysis of the cluster mdv1-mir-M9–M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek’s disease virus infection
JP2003528604A5 (enExample)
Shirakawa et al. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells
JP3974894B2 (ja) 腫瘍特異的プロモーターおよびその用途
JP2005523718A5 (enExample)
JP2018509154A5 (enExample)
CA2478616A1 (en) Use of adenoviruses mutated in the va genes for cancer treatment
CN103981155A (zh) 靶向肝癌溶瘤腺病毒的构建法和应用
Ulasov et al. Oncolytic adenoviruses: a thorny path to glioma cure
CN1259106C (zh) 一种抗癌靶向基因病毒药物的制备方法
Meijer et al. Adenovirus type 12 E1A down regulates expression of a transgene under control of a major histocompatibility complex class I promoter: evidence for transcriptional control
Curtin et al. Turning the gene tap off; implications of regulating gene expression for cancer therapeutics
JP2021505634A5 (enExample)
CN108018267A (zh) 一种靶向表观基因调控抗乙型肝炎病毒分子HBx1C及其应用
JP4402457B2 (ja) アデノウイルスｅ２後期プロモーターの制御のための、インビトロにおけるｙｂ−１の使用、及び、腫瘍の治療を目的とする医薬の製造のための当該使用を活用した核酸構築物の使用
Lyra-González et al. Adenoviral gene therapy in hepatocellular carcinoma: a review